Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) Company Bio
Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.
TARO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Taro Pharmaceutical Industries Ltd. To summarize, we found that Taro Pharmaceutical Industries Ltd ranked in the 30th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for TARO, they are:
In the past 4.97 years, Taro Pharmaceutical Industries Ltd has a compound free cash flow growth rate of -0.09%; that's higher than only 11.24% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Taro Pharmaceutical Industries Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -5.14. This coverage rate is greater than that of only 11.29% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NUVA, BIO, ZBH, CAH, and IONS can be thought of as valuation peers to TARO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Taro Pharmaceutical Industries Ltd. (NYSE:TARO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on May 20, 2020 ...